메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

EVERISE STRENGTHENS LEADERSHIP TEAM WITH CHIEF REVENUE OFFICER AND CHIEF FINANCIAL OFFICER APPOINTMENTS

PLANTATION, Fla., Aug. 11, 2025 -- Everise, a global leader in transforming customer experiences, today announced two senior leadership appointments as the company continues its growth trajectory and expansion in global markets. Industry veteran Robert Jimenez joins as Chief Revenue Officer (CRO), while accomplished finance leader Steven Amaya takes on the role of Chief Financial Officer (CFO). These strategic appointments come as Everise continues to expand its global footprint, scale its operations, and deepen its partnerships with some of the world's leading
- 김갑성 기자
- 2025-08-11 21:00
REVEALING STUDY HAS REJUVANT LEADING THE LONGEVITY PACK

Renowned Longevity Researcher Reveals Highlights of New Study to NBJ Conference Guests FERNANDINA BEACH, Fla., Aug. 11, 2025 -- Dr. Brian Kennedy, one of the world's leading Longevity researchers, gave a keynote presentation at the Nutritional Business Journal's annual CEO conference in Palos Verdes CA last week. Dr. Kennedy previewed highlights from his team's use of advanced AI driven statistics to analyze the data from a large longevity study of 4,260 health enthusiast subjects who purchased at least one saliva based DNA epigenetic test between 2020 and 2025. The subjects de
- 김갑성 기자
- 2025-08-11 20:06
AMI Pharm Advances AYP-101 to Phase 3, Paving the Way for a New Era in Fat-Reduction Injectable drugs

— Novel non-cytolytic injectable drug targets submental fat with significantly reduced pain and swelling— Phase 3 clinical trial underway in South Korea, following strong safety and efficacy results in earlier studies— AMI Pharm positions itself for global expansion in the multi-billion-dollar non-surgical aesthetics market SEOUL, South Korea, Aug. 11, 2025 -- AMI Pharm, a biotechnology company specializing in next-generation aesthetic solutions, today announced that its lead drug candidate, AYP-101, has entered a pivotal Phase 3 clinical trial for the treatment of submental fa
- 김갑성 기자
- 2025-08-11 20:00
"Senior Speed Stack" Introduces Emerging Sport Stacking to Help Reduce Cognitive Decline in the Elderly

Key Points: The Junior Chamber International (JCI) North District organized the "2025 Senior Speed Stack Closing Ceremony," introducing sport stacking to help delay cognitive decline in the elderly. Celebrity Tiffany Lau (Tiffany) participated in speed stacking activities with seniors. Assistant Professor of Teaching Senior Dr Mok Kam-Ming from Lingnan University's School of Interdisciplinary Studies, conducted a tracking study as part of the project, finding that seniors who consistently participated in speed stacking training showed a downward trend in stress and anxi
- 김갑성 기자
- 2025-08-11 19:17
Everest Medicines to Announce 2025 Interim Results on August 29, 2025

SHANGHAI, Aug. 11, 2025 -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that it will report its interim results for the six months ended June 30, 2025, and provide a business update on August 29, 2025. The Company will hold live conference calls in English and Mandarin on August 29, 2025, Beijing Time. The English session of the conference call will be held at 8:00 AM on August 29, 2025, Beijing
- 김갑성 기자
- 2025-08-11 17:11
WuXi Biologics Launches HEK 293 Stable Cell Line Platform WuXia293 Stable for Development and Manufacturing of Difficult-to-Express Molecules

WuXia293Stable platform demonstrates high titer, human glycosylation and improved product quality by eliminating or significantly alleviating truncation in difficult-to-express molecules. WuXia293Stable platform maintains stable expression and consistent product quality during long-term cell passages, enabling scalable clinical and commercial manufacturing. SHANGHAI, Aug. 11, 2025 -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of WuXia293Stable, a new platform designed for the developm
- 김갑성 기자
- 2025-08-11 16:30
Akeso Announces First Patient Dosed in Phase III Trial of Ivonescimab as Consolidation Therapy for Limited-Stage SCLC After Definitive Radiotherapy

HONG KONG, Aug. 11, 2025 -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its multicenter, randomized, double-blind Phase III study (AK112-311/HARMONi-9), evaluating ivonescimab, a first-in-class PD-1/VEGF bispecific antibody developed by Akeso, in small cell lung cancer (SCLC). This study is designed to assess the efficacy and safety of ivonescimab as consolidation therapy in patients with limited-stage small cell lung cancer (LS-SCLC) who have not experienced progression following standard concurrent chemoradiotherapy
- 김갑성 기자
- 2025-08-11 10:52
Philippines' AC Health partners with Singapore's ABC Impact in vision to transform health for every Filipino

MANILA, Philippines, Aug. 11, 2025 -- AC Health, the healthcare arm of Ayala Corporation, has secured a landmark investment from ABC Impact, the Singapore-based impact investor dedicated to Asia and backed by Temasek Trust and Temasek. This strategic investment marks ABC Impact's entry into the Philippine healthcare sector, expanding its regional footprint. Under the agreement, ABC Impact will infuse primary capital for a c.16% minority stake in AC Health. The investment will support AC Health's vision of transforming healthcare for every Filipino by building a se
- 김갑성 기자
- 2025-08-11 10:31
HistoIndex Marks Another Step Forward with FibroSIGHT™ Plus: Introducing AI-based Quantitative Analysis in Fibrosis Assessment

SINGAPORE, Aug. 11, 2025 -- HistoIndex, a pioneering leader in digital pathology solutions for chronic liver disease, has announced the launch of FibroSIGHT™ Plus, its second Laboratory Developed Test (LDT) available in the United States. Building on the foundation of FibroSIGHT™[1], which debuted just months earlier, FibroSIGHT™ Plus introduces an additional feature of automated quantitative analysis of fibrosis - a key advancement that enables more consistent and precise characterization at diagnosis and tracking of fibrosis in patients with Metabolic Dysfunction-associated Steatohepatitis
- 김갑성 기자
- 2025-08-11 09:00
Brain Navi Biotechnology's NaoTrac performs first surgeries in Spain

Brain Navi has officially landed in Spain! TAIPEI, Aug. 11, 2025 -- Such an achievement has been made possible through the first of many collaborations with our valued partner, Palex Healthcare. This milestone has been reached not only thanks to Palex's solid reputation and deep experience in the Spanish medical market, but also due to the trust and commitment of their team. Brain Navi CEO Jerry Chen stated, "Brain Navi is proud to work alongside a partner that shares our vision of surgical innovation and desire to improve the well-being of patients continuously."&nbs
- 김갑성 기자
- 2025-08-11 09:00

이전

11 12 13 14 15 16 17 18 19 20

많이 본 기사

최근기사

2025-08-30_SAT

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 08월 31일 01시 20분